整合二代测序的新生儿及婴儿胆汁淤积诊断流程的诊断效能
该观察性研究纳入125例≤1岁、胆汁淤积持续≥6周的患儿,在排除胆道闭锁后按临床模式分层选择单基因确认、聚焦虚拟 panel 或 trio 全外显子测序。50例接受基因检测,检出率60%,最终仅18例(14%)病因未明,提示临床结合基因评估的流程对新生儿/婴儿胆汁淤积有效。
要点
- 125例患儿中74例(59%)最终诊断为胆道闭锁,96例(77%)有陶土样便并快速评估排除胆道闭锁。
- 50例接受基因检测,检出率60%,Alagille综合征11例、PFIC2 6例、α1-抗胰蛋白酶缺乏3例、PFIC3 2例。
- 最终仅18/125(14%)病因未明,提示该临床驱动基因检测流程可提高遗传病诊断率。
核心结论
- 结合临床评估与基因检测的诊断流程对新生儿/婴儿胆汁淤积有效,遗传病检出率高。
- 该流程还可能使有色便的患儿获得非侵入性诊断。
研究设计与样本
- 2012至2017年在三级医疗中心开展的前瞻性队列观察性研究。
- 纳入≤1岁发生、持续≥6周的胆汁淤积患儿,旨在测量潜在单基因病的检出率。
- 排除胆道闭锁后,按临床模式选择单基因确认检测、聚焦虚拟panel或trio全外显子测序三种策略。
主要发现
- 共纳入125例患儿(66例女性,中位年龄2个月)。
- 96例(77%)有陶土样便并快速评估排除胆道闭锁,最终74例(59%)诊断为胆道闭锁。
- 50例接受基因检测:6例单基因确认、38例panel、6例因复杂表型行trio全外显子测序。
- 基因检测检出率为60%;最终诊断Alagille综合征11例、进行性家族性肝内胆汁淤积症2型6例、α1-抗胰蛋白酶缺乏3例、进行性家族性肝内胆汁淤积症3型2例,另7种遗传病各1例。
- 总体仅18/125(14%)病因未明。
临床怎么用
- 对持续≥6周的新生儿/婴儿胆汁淤积,应先快速评估排除胆道闭锁。
- 排除胆道闭锁后,可根据临床模式分层选择单基因确认、聚焦panel或trio全外显子测序。
- 有色便患儿也可通过该基因检测流程获得非侵入性诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the performance of a diagnostic protocol for neonatal/infantile cholestasis in which the main clinical patterns steered the early use of different genetic testing strategies. STUDY DESIGN: An observational study was conducted between 2012 and 2017 in a tertiary care setting on a prospective cohort of children with cholestasis occurring at ≤1 year of age and persisting ≥6 weeks, to measure the detection rate of underlying monogenic diseases. After the exclusion of biliary atresia, a clinically driven genetic testing was performed, entailing 3 different approaches with different wideness: confirmatory single-gene testing; focused virtual panels; and wide search through trio whole-exome sequencing. RESULTS: We enrolled 125 children (66 female, median age 2 months); 96 (77%) patients had hypocholic stools and were evaluated rapidly to exclude biliary atresia, which was the final diagnosis in 74 (59%). Overall, 50 patients underwent genetic testing, 6 with single confirmatory gene testing, 38 through panels, and 6 with trio whole-exome sequencing because of complex phenotype. The genetic testing detection rate was 60%: the final diagnosis was Alagille syndrome in 11, progressive familial intrahepatic cholestasis type 2 in 6, alpha-1-antitrypsin deficiency in 3, and progressive familial intrahepatic cholestasis type 3 in 2; a further 7 genetic conditions were identified in 1 child each. Overall, only 18 of 125 (14%) remained with an indeterminate etiology. CONCLUSIONS: This protocol combining clinical and genetic assessment proved to be an effective diagnostic tool for neonatal/infantile cholestasis, identifying inherited disorders with a high detection rate. It also could allow a noninvasive diagnosis in children presenting with colored stools.
引用
- Nicastro E, Di Giorgio A, Marchetti D, et al. Diagnostic Yield of an Algorithm for Neonatal and Infantile Cholestasis Integrating Next-Generation Sequencing. J Pediatr. 2019. PMID: 31160058. doi:10.1016/j.jpeds.2019.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。